Inspire(US:INSP)2025-05-05 20:58Company Overview & Financial Performance - Inspire Medical Systems highlights a significant underpenetrated U S market valued at over $10 billion[7] - The company reported revenue of over $800 million in 2024, marking a 28% year-over-year growth[7, 10] - The company has surpassed 100,000 patients receiving Inspire therapy[7, 75] - The company's gross margin for the first quarter was 84.7%[75] - FY2025 revenue is projected to be in the range of $940 million to $955 million, representing a 17%-19% growth over FY2024[70] Inspire Therapy & Market Dynamics - The company has reimbursement coverage in all 50 states, covering over 300 million U S lives[7, 9] - The domestic OSA market presents a substantial opportunity, with approximately 500,000 Inspire-eligible individuals[25] - Inspire patients experience a median AHI reduction from 33 events/hr at baseline to 10.2 events/hr at 12 months[44] - 91% of patients say Inspire is better compared against their previous experience with CPAP[47] GLP-1s and OSA - Claims data identified over 1,500 patients who were on a GLP-1 at the time of Inspire implant[122] - The BMI of Inspire patients was roughly 20% lower at the time of implant than all other OSA patients at the time of their OSA Dx[123]